Yuhei YAMAGUCHI· @yymgcmd · X·· 2 天前评分45
正文 · 机器翻译
在同时可获得 abemaciclib 和 ribociclib 的国家，如何在两者之间做出选择颇具挑战。
在日本，近期将辅助治疗 abemaciclib 扩展至 monarchE 队列 2，已在一定程度上缩小了两者在适用人群方面的差距。
#ESMO26
129 浏览 · 2 赞 · 0 转发 · 0 回复
会议摘要
1RO按 Rapid oral 1: Breast cancer, advanced stage 对上
Overall survival from the phase 3 postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapy
https://esmocongress.esmo.orgAssociation of p27 V109G SNP zygosity with outcomes and abemaciclib treatment effect in HR+, HER2– high-risk early breast cancer: Results from monarchE
https://esmocongress.esmo.orgMaintained iDFS benefit (Δ 5.3%) and favorable OS (Δ 2.1%) with adjuvant ribociclib after 6 years of follow up (all patients off ribo). Efficacy comparable to abema (monarchE), with different toxicity profile and wider population (N+ and high-risk N0). #ESMO26 #ESMOAmbassadors在 X 查看被引用的帖子
来源：Yuhei YAMAGUCHI · x.com